Unreasonable suppression! The Biden administration announced the latest semiconductor export restrictions to China. How will this affect various aspects?

1. The usa Biden administration has issued new controls on semiconductor exports to china, with over one hundred chinese entities being included in the 'entity list'; 2. The U.S. Department of Commerce has also introduced 'long-arm jurisdiction,' restricting third-party countries from providing products containing U.S. technology or chips to Chinese companies listed on the entity list, but the Netherlands, japan, and over 30 other countries are exempted; 3. The Chinese Ministry of Commerce and Ministry of Foreign Affairs respond: China will take necessary measures to resolutely defend its legitimate rights and interests.

cls.cnDec 2 18:38 ET

beijing tongrentang channel research: the high-end series has started to layout, there are still "gaps" in the out-of-hospital channels, and mergers and acquisitions have taken root in the in-hospital market | company research

① This Friday, the chairman of beijing tongrentang, Di Shubing, officially assumes the role of general manager of beijing tongrentang Group. ② The high-end imperial medicine series is primarily sold in beijing tongrentang pharmacies and remains hard to find in some city chain pharmacies. The company stated that the overall sales situation is in line with expectations. ③ beijing tongrentang Commercial Company acquired 51% of Honghui Medical for 0.105 billion, exploring the medical market, but there are still gaps in the outpatient medium and large chain market.

cls.cnNov 30 09:42 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27 09:29 ET

Rare opportunity to accurately 'escape the peak'? hongda high-tech holding reduces its shareholding in haining china leather market after ten years | Quick announcement.

1. Hongda High-Tech Holding sold 11.15 million shares of Haining China Leather Market, with a transaction amount of 71.65 million yuan. 2. The company holds a total of 30.3 million shares of Haining China Leather Market, which were acquired before the initial public offering. These shares were unlocked and listed for trading in 2014, and it has been ten years since then. 3. Haining China Leather Market experienced unusual fluctuations in the stock price in the past ten days, with five consecutive limit up movements from November 15th to November 21st, followed by a sharp decline from the 25th to the 27th. The closing price today is 4.88 yuan.

cls.cnNov 27 09:11 ET

After a 10-year wait! hongda high-tech holding "seizes market opportunities" to reduce shareholding in haining china leather market.

1. Hongda high-tech holding announced that it recently sold part of its stocks in haining china leather market for a total amount of 71.6589 million yuan, accounting for 0.87% of haining china leather market's total equity. 2. After the shareholding, hongda high-tech holding still holds 19.15 million shares of haining china leather market, accounting for 1.49% of the total equity.

cls.cnNov 27 07:56 ET

After consecutive years of losses, "abandoned"? Guangxi Wuzhou Zhongheng Group plans to transfer control of Chongqing Lummy Pharmaceutical | Quick Read Announcement.

①Guangxi Wuzhou Zhongheng Group plans to transfer the shares of Chongqing Lummy Pharmaceutical held directly by the company through public solicitation, which may lead to changes in the controlling shareholder and actual controller of the latter. ②The "story" of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019, and the following April it became the major shareholder of Chongqing Lummy Pharmaceutical, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous state of losses.

cls.cnNov 26 09:55 ET